Introduction
Lung cancer remains the number one cause of cancer death in the United States with an estimated 161 840 deaths in 2008 [1] . It is estimated that only 15-20% of patients ultimately prove to have resectable disease, but because of significant comorbidities, many are not deemed to be appropriate candidates for surgery from an operability standpoint. Recently, stereotactic body radiotherapy has been utilized in medically inoperable patients with early stage lung cancer. For those patients who are unresectable, chemotherapy with or without thoracic radiotherapy is the next best option in patients who can tolerate treatment. Although the histologic classification of bronchogenic carcinomas has long been recognized, the necessity for discrimination beyond the traditional dichotomy of small cell (SCLC) vs. nonsmall cell carcinomas (NSCLC) has only recently become elucidated.
For instance, bevacizumab, a monoclonal antibody directed against the vascular endothelial growth factor improves survival when used in combination with conventional chemotherapy in advanced NSCLC, but leads to unacceptable bleeding complications in patients with squamous cell carcinomas (SCC), making the exclusion of these patients mandatory [2, 3] . Likewise, the recognition that certain histologic subtypes of NSCLC respond better to specific chemotherapeutic agents (gemcitabine in SCC and permetrexed in non-SCC) [4] , along with the mounting evidence for the advantages of a targeted treatment approach to NSCLC (via monoclonal antibodies or small molecule tyrosine kinase inhibitors) [5, 6] warrant precise information that conventional morphologic examinations via light microscopy alone can no longer provide.
The considerable advances in genomics, transcriptomics and proteomics observed over the past few years are in the process of revolutionizing our approach to lung cancer diagnosis and treatment. They have also helped refine more traditional techniques such as immunohistochemistry (IHC) or fluorescent in-situ hybridization (FISH).
Once solely limited to resected lung cancer, they are increasingly applied to smaller biopsy specimens. This is of paramount importance as tissue samples obtained in advanced NSCLC are generally small-volume biopsies obtained by bronchoscopy and CT-guided biopsies. In this review, we will summarize the recent advances in molecular biology that may supplement morphologic examinations of tissue samples obtained by bronchoscopy with regards to screening and early diagnosis, precise histologic and cytologic diagnosis and predictors of response to treatment, within the context of NSCLC.
Screening and early diagnosis of lung cancer
Early diagnosis of NSCLC is thought to be important as surgery, with or without adjuvant treatment, continues to offer patients the best chance of cure. Bronchoscopy, particularly with the help of techniques such as auto-fluorescence bronchoscopy (AFB) and narrow-band imaging, may help identify, and occasionally treat, preinvasive lesions [7] . FISH using labeled DNA probes to detect chromosomal abnormalities has been successfully used in a variety of malignancies [8] [9] [10] . In a study from the Mayo Clinic, Halling et al.
[11] report the diagnostic accuracy of FISH for malignant lesions in addition to cytology for washings and brushings obtained during routine bronchoscopy with 4 DNA probes (locus-specific probes to 5p15, 7p12 (EGFR), 8q24 (C-MYC), and a centromeric probe to chromosome 6). Using polysomy (cells with gain of two or more of the 4 probes) as a criterion for FISH abnormality, sensitivity was markedly improved when compared with cytology alone (75% vs. 61%, P < 0.001) with a slight reduction in specificity that did not reach statistical significance (83% for brushings and 95% for washing specimens vs. 100% for cytology). Perhaps even more interesting is the marked improvement in sensitivity for peripheral lesions (63 vs. 33%). The reasons for this observation are unclear, but may be explained by the concept of field cancerization, which relates to the presence of small contingents of cells with genomic abnormalities at distance from the primary tumor that may be identified by FISH. This technique was subsequently applied as a reflex study in 343 patients referred for diagnostic bronchoscopy [12 ] . Of these, 294 had negative cytology results and were submitted to reflex FISH testing. Overall, sensitivity was markedly improved, particularly for peripheral lesions as 44% and 28% more cancers were detected for peripheral lesions of more than and less than 2 cm respectively, with few false positives. Overall, FISH detected 32% more lung cancers (18 central and 43 peripheral) than cytology alone.
FISH may also complement the information provided by AFB, as observed by Massion et al. [13] . Analyzing the genomic gain patterns identified by FISH in biopsies obtained via AFB in 70 individuals with preinvasive lesions (moderate dysplasia to carcinoma in situ), four probes (TP63, MYC, CEP3 and CEP6) were found to correlate significantly with lung cancer, with reported sensitivity and specificity for the combination of these four probes of 82% and 58% respectively. These findings, although preliminary, suggest that FISH may be helpful in clarifying the significance of dysplastic lesions identified via AFB. As the natural history of preinvasive lesions identified via bronchoscopy remains unclear, a tailored management based on FISH analysis of bronchoscopic lung biopsies could represent a substantial advance in the management of these patients.
Progression of preinvasive lesions to malignancy of lesions detected via AFB may also be heralded by loss of heterozygosity (LOH) of particular chromosomal markers [14] . Comparing LOH of 3p, 5q and 9p in 23 severe dysplasia and 31 carcinoma in-situ lesions, 3pLOH was strongly associated with progressive lesions, as defined by endobronchial treatment-resistant lesions or progression to invasive carcinoma over a 12-year period of follow-up. Although of preliminary nature, these results are encouraging and may provide further insight in the diagnostic strategy of preinvasive lesions.
Micro-RNAs (miRNAs) constitute a particular type of nontranscribed RNA involved in the regulation of translation of the mRNA. Using PCR amplification, Mascaux et al. [15] analyzed the global miRNA expression profiling of preinvasive lesions, again identified by AFB. They identified characteristic trends of expression and suggest a role for miRNA in the pathogenesis of lung carcinogenesis. As important, at least from a practical standpoint, miRNA expression was found to be highly predictive of the histologic grade of the lesions and suggests that recognition of these varying patterns of expression may ultimately lead to early diagnosis of lung cancer. The technical aspects of these techniques (PCR after microdissection) may, however, hamper their application in routine clinical practice.
Histologic diagnosis: recently identified molecular biomarkers
The traditional method of diagnosis of lung cancer relies on the morphological analysis of histologic features. Specific patterns include small vs. nonsmall cells, intercellular bridges and/or keratin pearls in SCC and gland formation and/or intracytoplasmic mucin in adenocarcinomas [16] . Overall, 20-30% of tumor samples cannot be precisely characterized on the usual preparations, and as such, techniques of IHC have been increasingly used; they have been reviewed elsewhere [17, 18] . These techniques can be applied to formalin-fixed, paraffin-embedded (FFPE) slides of tissue obtained surgically or via limited biopsies including bronchoscopic lung biopsies.
Techniques of microarray and gene expression profile analysis have recently allowed the identification of novel biomarkers. A recent study by Savci-Heijink et al. [19] evaluated the diagnostic accuracy of desmoglein 3 used as a marker for SCC. In that study, sensitivity and specificity of desmoglein 3 identified via IHC methods were respectively 98% [95% confidence interval (CI) 97-100%] and 99% (95% CI 95.6-100%), and seemed to correlate well with microarray analysis. Napsin-A, a protease involved in the metabolism of the surfactant was identified more consistently than thyroid transcription factor-1 (TTF-1) in lung adenocarcinomas as reported in a study by Bishop et al. [20] . The sensitivity was improved by 10% (83%), and the combination of the two was better than for each marker alone. The dual staining for TTF-1 and napsin-A by IHC may, therefore, prove useful in the diagnosis of lung adenocarcinoma, although positivity has been noted in renal cancer and thyroid malignancies.
The particular case of large cell carcinoma (LCC) remains problematic. In practice, the diagnosis encompasses those tumor samples that do not characterically exhibit features of either SCC or adenocarcinoma. With the evidence that subtypes of NSCLC seem to respond better to specific chemotherapy regimens, the identification of contingents of cells of squamous or glandular origin within these tumors may be of significant importance. Monica et al. [21] reported the results of IHC staining of desmocollin-3 (DSC-3), another marker of epithelial cells, in 62 LCC. Forty-five percent of LCC demonstrated positive staining for DSC-3, which was mutually exclusive of TTF-1, a marker typically negative in SCC. In cytological specimens obtained via transthoracic needle aspiration or bronchoalveolar lavage, DSC-3 staining correlated well with corresponding histology diagnoses. Whether further characterization of LCC will result in improved patient outcomes remains to be determined.
Ring et al. [22] used a sample of 551 surgical lung biopsies to determine the best combination of five IHC antibodies (TRIM29, CEA CAM5, SLC7A5, MUC1, and CK5/6) out of 400 of interest as suggested by gene expression profile analyses. A weighted algorithm using these five markers was then used on three validation cohorts to distinguish squamous cell carcinoma from adenocarcinoma in a total of 1111 small biopsy samples obtained from needle aspirations. Compared with the IHC with TP63 and TTF-1, this method resulted in half the rate of unclassifiable NSCLC, suggesting that this algorithm may be useful in the clinical setting, particularly when small biopsy samples make morphologic examination difficult. miRNA, as mentioned earlier, is a specific type of RNA involved in the posttranscriptional regulation of gene expression [23] . Several studies have reported specific patterns of expression among various types of NSCLC, and the techniques used have been successfully carried with limited tissue samples obtained bronchoscopically. In a recently published study, Lebanony et al. [24 ] report excellent sensitivity and specificity of has-miR-205, a marker of SCC, of 96% and 90% respectively. This assay was highly reproducible using RT-PCR on FFPE slides and was validated in an independent validation set. However, compared with techniques of IHC, this assay remains both time-consuming and difficult to justify from a cost-effectiveness standpoint. It is also uncertain how reproducible these assays are from one laboratory to another.
Natural history and response to treatment: contribution of molecular biology
The extraordinary advances in techniques of molecular biology observed over the past 5 years have led to significant improvements in our understanding of the molecular mechanisms leading to lung cancer and are revolutionizing our approach to the treatment of NSCLC. Inhibitors of the epidermal growth factor receptor (EGFR), whether inhibitors of the tyrosine kinase intracellular function of the receptor tyrosine kinase inhibitors (TKIs), erlotinib and gefitinib, or monoclonal antibodies directed against the extracellular receptor (cetuximab), have become an integral part in the armamentarium of the thoracic oncologist [5, 6] . There is now strong evidence that the EGFR-TKIs are best utilized in a particular subgroup of patients. Women, particularly of East Asian ethnicity, never smokers with a histologic diagnosis of adenocarcinoma seem to respond better to EGFR-TKIs [25, 26] . However, as reported in a landmark study, these clinical features may not be sensitive or specific enough to select patients who may benefit from these agents as opposed to conventional cytotoxic agents. Even in highly selected populations, EGFR mutations should be sought before consideration of treatment [6, 27] . Likewise, mutations of the KRAS gene have been shown to confer resistance to both erlotinib and gefitinib, although correlation with poorer survival remains unclear [28, 29] . The identification of these mutations, once requiring large size samples obtained from resected tumors, are now routinely performed on smaller biopsies, often the only material available for analysis in advanced nonsmall cell lung cancer [30] [31] [32] .
Several methods are being used to detect EGFR mutations on bronchoscopic biopsies or fine needle aspirations. Because of the fragility of the genetic material, particularly after processing of tissue samples obtained by bronchoscopy, techniques such as IHC, which can be Advances in the diagnosis of lung cancer Maldonado and Jett 317 performed on FFPE samples of any size, could offer a major advantage, and several antibodies have been studied targeting the most common EGFR mutations on exons 19 and 21 with excellent results [33 ] . Techniques of IHC, however, are semi-quantitative by nature, poorly standardized and the results are highly dependent on the type of antibody used, antibody batch, staining methods and scoring protocols [34] . The detection of EGFR expression by IHC was used to select patients for the FLEX trial comparing cetuximab in addition to a cisplatinum doublet vs. cisplatinum doublet alone, with significantly improved survival [5] . This was justified as EGFR is expressed in only 50-90% of all NSCLC and as cetuximab in addition to conventional therapy was not found to be of benefit in an unselected population [35, 36] . However, as opposed to EGFR tyrosine kinase mutational status and response to TKIs, the EGFR protein quantity is an unproven predictor of response to EGFR monoclonal antibody or EGFR-TKI therapy.
Direct sequencing via PCR is used increasingly on smaller biopsy samples, including CT-guided biopsies and bronchoscopic lung biopsies. A recent study suggests that mediastinal lymph-node biopsies obtained by endobronchial ultrasound-guided biopsies could be excellent specimens for this type of analysis [37] . The technical limitations of direct sequencing on small biopsy specimen remain, however, substantial [38] . Careful isolation of tumor cells typically requires macrodissection and microdissection, and the genetic material of FFPE samples may be altered and lead to PCR artifact. For small-volume biopsies, a variety of high-sensitivity techniques may offer benefits but they remain of unclear clinical value: high-resolution melting analysis, high-performance liquid chromatography and amplified refractory mutation system, among others [30, [39] [40] [41] [42] [43] . These techniques may identify low levels of mutations in heterogeneous samples with a limited amount of tumor cells. The clinical implications of the mutations detected by these methods is, however, currently uncertain. A set of recommendations by the Biomarkers of Response to Epidermal Growth Factor Receptor Inhibitors in Non-Small-cell Lung Cancer Working group has been published, and highlights the need for standardization of these procedures [38] .
Another promising area of research relies on the identification of molecular predictors of response to conventional cytotoxic chemotherapy. The excision repair cross-complementing group 1 (ERCC1) gene expression, and ribonucleotide reductase subunit 1 (RRM1) and thymidylate synthase enzymatic function confer resistance to cisplatinum, gemcitabine and permetrexed, respectively [44] [45] [46] [47] [48] . Measurement of these gene expressions levels may alter the current treatment of NSCLC and lead to individualized therapy. The prospective pilot study of molecular analyses-directed individualized therapy for advanced NSCLC used bronchoscopic biopsy samples and transthoracic needle aspirations to determine ERCC1 and RRM1 status via RT-PCR to select chemotherapy protocols and demonstrated both feasibility and potentially improved clinical outcomes [49] . Several confirmatory studies using similar algorithms are ongoing.
Direct gene sequencing of bronchoscopic biopsy samples remains, however, a fruitful venue of research and may ultimately permit, in addition to histologic and clinical characteristics, the identification of specific predictive patterns of gene expression, or 'gene signatures'. Several models have been proposed in the literature, such as the five-gene signature or the lung metagene model, but have so far required resected, early stage tumors [50, 51] . As described by Baty et al. [52 ] , whole genome amplification may allow multiple simultaneous molecular analyses on low-volume biopsies. Using this technique on both surgical and minute bronchoscopic lung biopsies, they showed that accurate tumor classification and prediction of survival via gene expression profile analysis seems both feasible and accurate, as confirmed on an independent data set.
Conclusion
Advances in molecular biology have transformed our understanding of lung cancers, particularly NSCLC, and are in the process of revolutionizing the approach to the management of these patients. The necessity to identify specific patterns of protein and genomic expression have resulted in a paradigm shift that requires the application of complex techniques to smaller biopsy samples obtained from patients for whom resection surgery is neither indicated nor generally feasible. Advanced molecular techniques could potentially offer earlier diagnosis, accurate characterization of the histologic subtype of NSCLC and insight into the prognosis of the disease and the expected response to chemotherapy or targeted therapy. These techniques remain, however, in their early development and considerable efforts to standardize them are necessary. 
